Chronic Treatment with a Promnesiant GABA-A α5-Selective Inverse Agonist Increases Immediate Early Genes Expression during Memory Processing in Mice and Rectifies Their Expression Levels in a Down Syndrome Mouse Model
about
Neurological phenotypes for Down syndrome across the life spanSynaptopathies: synaptic dysfunction in neurological disorders - A review from students to studentsGABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism.Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives.Estrogen and the prefrontal cortex: towards a new understanding of estrogen's effects on executive functions in the menopause transition.Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brainMolecular and cellular alterations in Down syndrome: toward the identification of targets for therapeuticsFrom abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome.Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome.Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.Weaker control of the electrical properties of cerebellar granule cells by tonically active GABAA receptors in the Ts65Dn mouse model of Down's syndrome.The GABAergic Hypothesis for Cognitive Disabilities in Down SyndromeCognitive and pharmacological insights from the Ts65Dn mouse model of Down syndromeRodent models in Down syndrome research: impact and future opportunities.
P2860
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
P2860
Chronic Treatment with a Promnesiant GABA-A α5-Selective Inverse Agonist Increases Immediate Early Genes Expression during Memory Processing in Mice and Rectifies Their Expression Levels in a Down Syndrome Mouse Model
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Chronic Treatment with a Promn ...... in a Down Syndrome Mouse Model
@ast
Chronic Treatment with a Promn ...... in a Down Syndrome Mouse Model
@en
type
label
Chronic Treatment with a Promn ...... in a Down Syndrome Mouse Model
@ast
Chronic Treatment with a Promn ...... in a Down Syndrome Mouse Model
@en
prefLabel
Chronic Treatment with a Promn ...... in a Down Syndrome Mouse Model
@ast
Chronic Treatment with a Promn ...... in a Down Syndrome Mouse Model
@en
P2093
P2860
P356
P1476
Chronic Treatment with a Promn ...... in a Down Syndrome Mouse Model
@en
P2093
A Loistron
B Delatour
J Braudeau
L Dauphinot
M C Potier
P2860
P304
P356
10.1155/2011/153218
P577
2011-10-19T00:00:00Z